CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
Estrogen +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000176
NCT00000176Phase 3Completed
CompareCT.gov

Alzheimer's Disease Prevention Trial. A Multi-center, Randomized, Double-blind Placebo Controlled Trial of Estrogens to Prevent Alzheimer's Disease and Loss of Memory in Women.

National Institute on Aging (NIA)·interventional·Posted Nov 1, 1999·Updated Nov 5, 2010

In Brief

A Phase 3 clinical trial evaluating Estrogen and Estrogen and Progesterone for Alzheimer Disease and Memory Disorders. Completed, across 22 sites.

Detailed Summary

This is a three-year study to determine if estrogens can prevent memory loss and Alzheimer's disease in women with a family history of Alzheimer's disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease, Memory Disorders
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 1, 1999
Primary CompletionSep 1, 2007
TodayJul 2, 2026
Posted 26.7 years ago

Interventions

Estrogendrug

Estrogen and Progesteronedrug